Genomic and Proteomic Analysis of Disease Progression in Idiopathic Pulmonary Fibrosis (IPF) (GAP)

August 26, 2026 updated by: Kevin F. Gibson, University of Pittsburgh

Genomic and Proteomic Analysis of Disease Progression in Idiopathic Pulmonary Fibrosis

The purpose of the study is to identify genetic and biologic markers that may predict the loss of lung function due to idiopathic pulmonary fibrosis. The studies will compare genetic and biologic markers of samples to changes in symptoms. The ultimate goal is to predict if or when patients are likely to experience a rapid decline in lung function due to disease progression.

Study Overview

Status

Recruiting

Conditions

Detailed Description

People who are diagnosed with idiopathic pulmonary fibrosis are asked to participate in this study. The subject must be treated at the Dorothy P. and Richard P. Simmons Center for Interstitial Lung Disease. Subjects, if consented, are required to perform tests so that research data can be collected. At the initial visit, patients are subject to having a blood draw, pulmonary function testing, echocardiograms, and CT scans as well as completing several questionnaires designed to measure how the patient is feeling. Follow up visits are then scheduled in 3-4 month intervals. Every 3-4 months blood samples will be collected while every 6-8 months the questionnaires will administered. If the patient enters a stage of accelerated decline in lung function, a bronchoscopy will be performed to collect residual bronchoalveolar lavage fluid for testing. All of the results of clinical and laboratory testing will be placed into the subjects research file.

Study Type

Observational

Enrollment (Estimated)

500

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

Study Locations

  • United States
    • Pennsylvania
      • Pittsburgh, Pennsylvania, United States, 15213
        • Recruiting
        • Michelle F MacPherson
        • Contact:
        • Sub-Investigator:
          • Kristen Veraldi, M.D.
        • Sub-Investigator:
          • Michelle Meyers, BSN, RN
        • Sub-Investigator:
          • Luis Ortiz, MD
        • Sub-Investigator:
          • Prabhir Ray, PhD
        • Sub-Investigator:
          • Daniel J. Kass, M.D.
        • Sub-Investigator:
          • Michelle F. MacPherson, BS, MAT
        • Principal Investigator:
          • Kevin F Gibson, MD
        • Sub-Investigator:
          • Morgan L Carnahan, BS
        • Sub-Investigator:
          • Yingze Zhang, PhD
        • Contact:
        • Sub-Investigator:
          • Daniel Sullivan, MD
        • Sub-Investigator:
          • Eleanor Valenzi, MD
        • Sub-Investigator:
          • Seyed Mehdi Nouraie, MD
        • Sub-Investigator:
          • Xiaoping Chen, MS
        • Sub-Investigator:
          • Gillian Goobie, MD PhD
        • Sub-Investigator:
          • John Sembrat, PhD
        • Sub-Investigator:
          • Timothy Corcoran, PhD
        • Sub-Investigator:
          • Xiaoyun Li, MD

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

14 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Sampling Method

Non-Probability Sample

Study Population

Patients aged 18 and older who have been diagnosed with IPF and referred by a Simmons Center doctor.

Description

Inclusion Criteria:

  • Patients who are 18 or older
  • Diagnosis of Idiopathic Pulmonary Fibrosis
  • Treated at the Simmons Center

Exclusion Criteria:

  • Other Lung Illness

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Observational Models: Cohort
  • Time Perspectives: Other

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

University of Pittsburgh

Investigators

  • Principal Investigator: Kevin F Gibson, MD, University of Pittsburgh - Dorothy P. and Richard P. Simmons Center for Interstitial Lung Disease

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Helpful Links

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

October 1, 2005

Primary Completion (Estimated)

July 1, 2030

Study Completion (Estimated)

July 1, 2030

Study Registration Dates

First Submitted

September 6, 2006

First Submitted That Met QC Criteria

September 7, 2006

First Posted (Estimated)

September 8, 2006

Study Record Updates

Last Update Posted (Actual)

August 27, 2026

Last Update Submitted That Met QC Criteria

August 26, 2026

Last Verified

August 1, 2026

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • STUDY19040326

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe